BNP Paribas Financial Markets Raises Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

BNP Paribas Financial Markets boosted its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 141.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,520 shares of the company’s stock after acquiring an additional 10,843 shares during the quarter. BNP Paribas Financial Markets’ holdings in Pediatrix Medical Group were worth $215,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MD. nVerses Capital LLC acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth $31,000. Innealta Capital LLC acquired a new position in Pediatrix Medical Group during the second quarter worth about $33,000. Quest Partners LLC increased its holdings in Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $72,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Wall Street Analysts Forecast Growth

MD has been the subject of several research analyst reports. Truist Financial raised their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho raised their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. UBS Group lifted their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Macquarie began coverage on shares of Pediatrix Medical Group in a research note on Monday. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and an average target price of $16.42.

Insider Transactions at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Price Performance

NYSE:MD opened at $14.46 on Tuesday. Pediatrix Medical Group, Inc. has a 12-month low of $6.62 and a 12-month high of $16.41. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -4.73, a price-to-earnings-growth ratio of 2.00 and a beta of 1.57. The company’s 50-day moving average is $14.02 and its two-hundred day moving average is $10.83. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.29 earnings per share. Research analysts expect that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.